Nevro

Nevro is a global medical device company with a mission to enhance the quality of life for patients enduring chronic pain. Founded in 2006, the company's focus on innovation has been evident in its HFX technology, which incorporates enduring technologies, optimized therapies, and individualized patient support. This comprehensive solution, known as HFX, includes the Senza spinal cord stimulation system as well as support services for chronic pain treatment, including painful diabetic neuropathy at a frequency of 10 kHz. The company's commitment to innovation is captured in their slogan: "We Believe True Innovation Transforms More Lives." Nevro's latest funding round saw a $200.00MPost-IPO Debt investment by Braidwell on 30 November 2023. Although headquartered in the United States, Nevro is making a global impact in the biotechnology, healthcare, manufacturing, and pharmaceutical industries.